Effects of COVID-19 Lockdown on Glucose Control: Continuous Glucose Monitoring Data From People With Diabetes on Intensive Insulin Therapy
Author(s) -
Ernesto Maddaloni,
Lucia Coraggio,
Silvia Pieralice,
Angela Carlone,
Paolo Pozzilli,
Raffaella Buzzetti
Publication year - 2020
Publication title -
diabetes care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.636
H-Index - 363
eISSN - 1935-5548
pISSN - 0149-5992
DOI - 10.2337/dc20-0954
Subject(s) - medicine , diabetes mellitus , insulin , type 1 diabetes , ambulatory , insulin pump , covid-19 , glycemic , continuous glucose monitoring , disease , pediatrics , emergency medicine , intensive care medicine , endocrinology , infectious disease (medical specialty)
The coronavirus disease 2019 (COVID-19) outbreak forced Italy to begin lockdown on 9 March 2020. This suddenly changed the daily routine of people with diabetes, increasing sedentary behavior, changing eating patterns, and increasing their psychological burden (1,2), all of which may result in changes in glucose control. This is especially relevant for patients on complex therapeutic regimens such as multiple daily injections (MDI) of insulin or continuous subcutaneous insulin infusion (CSII). Therefore, the COVID-19 lockdown is an unprecedented model to investigate how acute changes in lifestyle affect glucose control in diabetes.To investigate the effects of lockdown on ambulatory glucose metrics, defined according to the international consensus on time in range (TIR) (3), we performed an analysis of continuous glucose monitoring (CGM) data of the 14 days preceding (baseline: 24 February to 8 March 2020) and following (lockdown: 10 March to 25 March 2020) the extension of lockdown to the whole of Italy in people with diabetes on MDI or CSII. After exclusion of individuals unable to upload data on online platforms or who had contact with diabetologists for therapeutic changes, 55 adults (43.6% male, median [25th, 75th percentile] age 41 [28, 49] years, disease duration 11 [5, 23] years) with diabetes (90.9% autoimmune, 5.5% type 2, 3.6% post-pancreatectomy) treated with MDI (≥4 insulin injections per day, 50.9%) or CSII (49.1%) …
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom